The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | “Off-the-shelf” CAR-T: future prospects
Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the potential of having “off-the-shelf” chimeric antigen receptor T-cell (CAR-T) therapies, outlining existing studies and results so far, and highlighting the need for increased lymphodepletion when using allogeneic CAR T-cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Dr Stephan Grupp, MD, PhD, has received research support from Novartis, Servier, Vertex and Kite; and has participated in study steering committees, consulting, or scientific advisory boards with Novartis, Allogene, Adaptimmune, TCR2, Cabaletta, Juno, CBMG, GlaxoSmithKline, Cellectis, Johnson & Johnson/Janssen, CRISPR/Vertex, Roche, Humanigen and Jazz.
